Castle Biosciences, Inc. Share Price
Stocks
CSTL
US14843C1053
Medical Equipment, Supplies & Distribution
|
Real-time Estimate
Cboe BZX
01:12:45 10/09/2026 am IST
|
5-day change | 1st Jan Change | ||
| 32.36 USD | -1.24% |
|
-2.93% | -16.61% |
| 28/08 | Castle Biosciences Insider Sold Shares Worth $317,112, According to a Recent SEC Filing | MT |
| 17/08 | Castle Biosciences Gets Approval for Dual Listing on Nasdaq Texas | MT |
| Market Cap | 100.08Cr 86Cr 81Cr 74Cr 138.24Cr 9.52TCr 138.79Cr 961.05Cr 371.44Cr 4.85TCr 375.8Cr 367.63Cr 15TCr | P/E 2026 * |
-25.8x | P/E 2027 * | -33.1x |
|---|---|---|---|---|---|
| Enterprise Value | 100.08Cr 86Cr 81Cr 74Cr 138.24Cr 9.52TCr 138.79Cr 961.05Cr 371.44Cr 4.85TCr 375.8Cr 367.63Cr 15TCr | EV / Sales 2026 * |
2.68x | EV / Sales 2027 * | 2.44x |
| Free-Float |
97.56% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| CSTL | Delayed | |
CBOE
| CSTL | Real-time | |
|
Tradegate
| 086 | Real-time | |
|
Deutsche Boerse AG
| 086 | Delayed | |
|
Deutsche Boerse AG
| 086 | End-of-day quote |
Last Transcript : Castle Biosciences, Inc.
| 1 day | -0.99% | ||
| 1 week | -2.93% | ||
| Current month | -1.79% | ||
| 1 month | +0.28% | ||
| 3 months | +53.89% | ||
| 6 months | +20.06% | ||
| Current year | -16.61% |
| 1 week | 31.98 |  | 34 |
| 1 month | 28.72 | | 35.2 |
| Current year | 17.72 | | 44.28 |
| 1 year | 17.72 | | 44.28 |
| 3 years | 12.07 | | 44.28 |
| 5 years | 9.26 | | 78.47 |
| 10 years | 9.26 | | 107.69 |
| Manager | Title | Age | Since |
|---|---|---|---|
Derek Maetzold
CEO | Chief Executive Officer | 64 | 01/09/2007 |
Franklin Stokes
DFI | Director of Finance/CFO | 56 | 01/12/2017 |
Johnson Clare
CTO | Chief Tech/Sci/R&D Officer | - | 01/07/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Derek Maetzold
BRD | Director/Board Member | 64 | 01/09/2007 |
Daniel Bradbury
CHM | Chairman | 64 | 01/09/2014 |
G. Cole
BRD | Director/Board Member | 70 | 06/12/2018 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 01/09/26 | Exercice | Chief Operating Officer | 12,456 | 0.0408% | ||
| 31/08/26 | Sell | Executive/Senior Manager | -1,730 | 0.0057% | ||
| 28/08/26 | Exercice | Founder | 43,416 | 0.1421% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.24% | -2.93% | +31.60% | +72.92% | 100.08Cr | |
| +0.94% | +0.00% | +174.34% | +388.66% | 2.16TCr | |
| -0.49% | -5.16% | -37.33% | -22.13% | 986.24Cr | |
| +2.00% | +8.22% | +394.19% | +38.99% | 854.71Cr | |
| -2.74% | -2.10% | -28.48% | - | 701.4Cr | |
| +0.44% | +0.13% | +83.29% | +54.46% | 655.6Cr | |
| -1.42% | -3.08% | -27.94% | -20.49% | 583.58Cr | |
| +0.52% | -3.12% | -9.80% | -20.29% | 423.84Cr | |
| -2.77% | -5.58% | +65.48% | +79.79% | 419.83Cr | |
| -0.53% | -3.11% | -24.32% | -30.15% | 274.4Cr | |
| Average | -0.45% | -1.03% | +62.10% | +60.20% | 716Cr | |
| Weighted average by Cap. | +0.06% | -0.88% | +99.84% | +139.16% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 37Cr 32Cr 30Cr 28Cr 52Cr 3.55TCr 52Cr 358.09Cr 138.4Cr 1.81TCr 140.02Cr 136.98Cr 5.73TCr | 41Cr 35Cr 33Cr 30Cr 57Cr 3.9TCr 57Cr 393.17Cr 151.96Cr 1.98TCr 153.74Cr 150.4Cr 6.29TCr |
| Net income | -3.8Cr -3.27Cr -3.08Cr -2.81Cr -5.25Cr -361.91Cr -5.27Cr -37Cr -14Cr -184.38Cr -14Cr -14Cr -584.11Cr | -2.78Cr -2.39Cr -2.25Cr -2.05Cr -3.83Cr -264.07Cr -3.85Cr -27Cr -10Cr -134.53Cr -10Cr -10Cr -426.2Cr |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 10/26/10 | $32.44 | -0.98% | 1,00,108 |
| 08/26/08 | $32.76 | -0.46% | 2,17,020 |
| 04/26/04 | $32.91 | +0.80% | 1,87,725 |
| 03/26/03 | $32.65 | -2.30% | 2,68,012 |
| 02/26/02 | $33.42 | -0.06% | 2,00,265 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CSTL Stock
Select your edition
All financial news and data tailored to specific country editions
